The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
Summary Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clini...
Gespeichert in:
Veröffentlicht in: | Immunology 2013-02, Vol.138 (2), p.105-115 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 115 |
---|---|
container_issue | 2 |
container_start_page | 105 |
container_title | Immunology |
container_volume | 138 |
creator | Lindau, Dennis Gielen, Paul Kroesen, Michiel Wesseling, Pieter Adema, Gosse J. |
description | Summary
Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies. |
doi_str_mv | 10.1111/imm.12036 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3575763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3311575031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</originalsourceid><addsrcrecordid>eNqNkctqFTEYgINY7LG68AUk4Eah0-YySWa6EKRYW2hxc1yHTJJp02Ymx2TSw9n5CD6jT2KO01NUEMwml__Lx38B4BVGR7isYzcMR5ggyp-ABaacVYRx8RQsEMJtRRrE9sHzlG7LlSLGnoF9QgnmHJEFWC9vLCz_8xhSXq2iTcndWzjlIeQIRzutQ7w7gcPG-uDMj2_fjY0FMHBHhwi19T4dwmivs1dTiBu4nN-gGg0c1ZSj8vDOeW_jLvQC7PXKJ_vyYT8AX84-Lk_Pq8vPny5OP1xWuhacV3Vnuqa3RDWaGNO0umOiU1QroXhreN2hti_nngoqrFBEa14IhupO9A0Thh6A97N3lbvBGm3HqSQjV9ENKm5kUE7-GRndjbwO95IWjeC0CN4-CGL4mm2a5ODStgQ12pCTxKRhqG0ZRv-BCsoahtu6oG_-Qm9Lv8fSCYkZ4W0jENkK382UjiGlaPvHvDGS28nLMjn5a_KFff17oY_kbtQFOJ6BtfN282-TvLi6mpU_AVUjvDw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1526987020</pqid></control><display><type>article</type><title>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Lindau, Dennis ; Gielen, Paul ; Kroesen, Michiel ; Wesseling, Pieter ; Adema, Gosse J.</creator><creatorcontrib>Lindau, Dennis ; Gielen, Paul ; Kroesen, Michiel ; Wesseling, Pieter ; Adema, Gosse J.</creatorcontrib><description>Summary
Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.</description><identifier>ISSN: 0019-2805</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1111/imm.12036</identifier><identifier>PMID: 23216602</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Animals ; Antigen-Presenting Cells - immunology ; Antigen-Presenting Cells - pathology ; Cell Communication - immunology ; Humans ; Immune Tolerance ; immunocombination therapy ; Immunotherapy - methods ; Medical research ; Myeloid Cells - immunology ; Myeloid Cells - pathology ; myeloid‐derived suppressor cell ; natural killer T cell ; Natural Killer T-Cells - immunology ; Natural Killer T-Cells - pathology ; Neoplasms - immunology ; Neoplasms - pathology ; Neoplasms - therapy ; regulatory T cell ; Review ; T cell receptors ; T-Lymphocytes, Regulatory - immunology ; T-Lymphocytes, Regulatory - pathology ; tumour microenvironment</subject><ispartof>Immunology, 2013-02, Vol.138 (2), p.105-115</ispartof><rights>2012 Nijmegen Centre for Molecular Life Sciences © 2012 Blackwell Publishing Ltd</rights><rights>2012 Nijmegen Centre for Molecular Life Sciences Immunology © 2012 Blackwell Publishing Ltd.</rights><rights>Copyright © 2013 Blackwell Publishing Ltd</rights><rights>Copyright © 2013 Blackwell Publishing Ltd 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</citedby><cites>FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575763/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575763/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1416,1432,27922,27923,45572,45573,46407,46831,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23216602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindau, Dennis</creatorcontrib><creatorcontrib>Gielen, Paul</creatorcontrib><creatorcontrib>Kroesen, Michiel</creatorcontrib><creatorcontrib>Wesseling, Pieter</creatorcontrib><creatorcontrib>Adema, Gosse J.</creatorcontrib><title>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</title><title>Immunology</title><addtitle>Immunology</addtitle><description>Summary
Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.</description><subject>Animals</subject><subject>Antigen-Presenting Cells - immunology</subject><subject>Antigen-Presenting Cells - pathology</subject><subject>Cell Communication - immunology</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>immunocombination therapy</subject><subject>Immunotherapy - methods</subject><subject>Medical research</subject><subject>Myeloid Cells - immunology</subject><subject>Myeloid Cells - pathology</subject><subject>myeloid‐derived suppressor cell</subject><subject>natural killer T cell</subject><subject>Natural Killer T-Cells - immunology</subject><subject>Natural Killer T-Cells - pathology</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>regulatory T cell</subject><subject>Review</subject><subject>T cell receptors</subject><subject>T-Lymphocytes, Regulatory - immunology</subject><subject>T-Lymphocytes, Regulatory - pathology</subject><subject>tumour microenvironment</subject><issn>0019-2805</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctqFTEYgINY7LG68AUk4Eah0-YySWa6EKRYW2hxc1yHTJJp02Ymx2TSw9n5CD6jT2KO01NUEMwml__Lx38B4BVGR7isYzcMR5ggyp-ABaacVYRx8RQsEMJtRRrE9sHzlG7LlSLGnoF9QgnmHJEFWC9vLCz_8xhSXq2iTcndWzjlIeQIRzutQ7w7gcPG-uDMj2_fjY0FMHBHhwi19T4dwmivs1dTiBu4nN-gGg0c1ZSj8vDOeW_jLvQC7PXKJ_vyYT8AX84-Lk_Pq8vPny5OP1xWuhacV3Vnuqa3RDWaGNO0umOiU1QroXhreN2hti_nngoqrFBEa14IhupO9A0Thh6A97N3lbvBGm3HqSQjV9ENKm5kUE7-GRndjbwO95IWjeC0CN4-CGL4mm2a5ODStgQ12pCTxKRhqG0ZRv-BCsoahtu6oG_-Qm9Lv8fSCYkZ4W0jENkK382UjiGlaPvHvDGS28nLMjn5a_KFff17oY_kbtQFOJ6BtfN282-TvLi6mpU_AVUjvDw</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Lindau, Dennis</creator><creator>Gielen, Paul</creator><creator>Kroesen, Michiel</creator><creator>Wesseling, Pieter</creator><creator>Adema, Gosse J.</creator><general>Wiley Subscription Services, Inc</general><general>Blackwell Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QR</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201302</creationdate><title>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</title><author>Lindau, Dennis ; Gielen, Paul ; Kroesen, Michiel ; Wesseling, Pieter ; Adema, Gosse J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4766-4bdb8fe2a8c2dd89cb57ba3ca7a69d64b09fa7af3737e7a2cc6b57504b7f857d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antigen-Presenting Cells - immunology</topic><topic>Antigen-Presenting Cells - pathology</topic><topic>Cell Communication - immunology</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>immunocombination therapy</topic><topic>Immunotherapy - methods</topic><topic>Medical research</topic><topic>Myeloid Cells - immunology</topic><topic>Myeloid Cells - pathology</topic><topic>myeloid‐derived suppressor cell</topic><topic>natural killer T cell</topic><topic>Natural Killer T-Cells - immunology</topic><topic>Natural Killer T-Cells - pathology</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>regulatory T cell</topic><topic>Review</topic><topic>T cell receptors</topic><topic>T-Lymphocytes, Regulatory - immunology</topic><topic>T-Lymphocytes, Regulatory - pathology</topic><topic>tumour microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindau, Dennis</creatorcontrib><creatorcontrib>Gielen, Paul</creatorcontrib><creatorcontrib>Kroesen, Michiel</creatorcontrib><creatorcontrib>Wesseling, Pieter</creatorcontrib><creatorcontrib>Adema, Gosse J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindau, Dennis</au><au>Gielen, Paul</au><au>Kroesen, Michiel</au><au>Wesseling, Pieter</au><au>Adema, Gosse J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells</atitle><jtitle>Immunology</jtitle><addtitle>Immunology</addtitle><date>2013-02</date><risdate>2013</risdate><volume>138</volume><issue>2</issue><spage>105</spage><epage>115</epage><pages>105-115</pages><issn>0019-2805</issn><eissn>1365-2567</eissn><abstract>Summary
Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>23216602</pmid><doi>10.1111/imm.12036</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0019-2805 |
ispartof | Immunology, 2013-02, Vol.138 (2), p.105-115 |
issn | 0019-2805 1365-2567 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3575763 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; IngentaConnect Free/Open Access Journals; Wiley Online Library All Journals; PubMed Central |
subjects | Animals Antigen-Presenting Cells - immunology Antigen-Presenting Cells - pathology Cell Communication - immunology Humans Immune Tolerance immunocombination therapy Immunotherapy - methods Medical research Myeloid Cells - immunology Myeloid Cells - pathology myeloid‐derived suppressor cell natural killer T cell Natural Killer T-Cells - immunology Natural Killer T-Cells - pathology Neoplasms - immunology Neoplasms - pathology Neoplasms - therapy regulatory T cell Review T cell receptors T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - pathology tumour microenvironment |
title | The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A57%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immunosuppressive%20tumour%20network:%20myeloid%E2%80%90derived%20suppressor%20cells,%20regulatory%20T%20cells%20and%20natural%20killer%20T%20cells&rft.jtitle=Immunology&rft.au=Lindau,%20Dennis&rft.date=2013-02&rft.volume=138&rft.issue=2&rft.spage=105&rft.epage=115&rft.pages=105-115&rft.issn=0019-2805&rft.eissn=1365-2567&rft_id=info:doi/10.1111/imm.12036&rft_dat=%3Cproquest_pubme%3E3311575031%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1526987020&rft_id=info:pmid/23216602&rfr_iscdi=true |